Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early abnormal fibrinolysis and mortality in patients with thermal injury: a prospective cohort study.

BJS open·2021
Same author

Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Effects of an acidic environment on coagulation dynamics.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Activation, activity and inactivation of factor VIII in factor VIII products.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Anticoagulation by factor Xa inhibitors.

T Orfeo1, S Butenas, K E Brummel-Ziedins

  • 1Department of Biochemistry, University of Vermont, Colchester, VT, USA.

Journal of Thrombosis and Haemostasis : JTH
|May 25, 2010
PubMed
Summary
This summary is machine-generated.

Selective factor Xa inhibitors like Rivaroxaban show promise for thrombotic disorders. Fondaparinux’s effectiveness in acute settings may stem from its anti-FXa and anti-FIXa activities, not just anti-FXa inhibition.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

  • Pharmacology and Toxicology
  • Biochemistry
  • Computational Biology

Background:

  • Blood coagulation regulation is vital for managing thrombotic disorders.
  • Selective targeting of factor Xa (FXa) is a key therapeutic strategy.
  • Understanding anticoagulant mechanisms is crucial for clinical application.

Purpose of the Study:

  • To evaluate anticoagulant strategies targeting FXa.
  • To compare the efficacy of antithrombin (AT)-dependent (fondaparinux) and AT-independent (Rivaroxaban) FXa inhibitors.
  • To assess these agents in both long-term and acute clinical application contexts.

Main Methods:

  • Utilized a deterministic computational model of tissue factor (Tf)-initiated thrombin generation.
  • Employed empirical experimental systems: synthetic coagulation proteome reconstruction and whole blood model.
  • Evaluated fondaparinux and Rivaroxaban in regimens simulating long-term and acute anticoagulation.

Main Results:

  • Computational models accurately predicted anticoagulant efficacy, aligning with empirical data.
  • Rivaroxaban demonstrated superior suppression of ongoing coagulation compared to fondaparinux.
  • Model systems were consistent with recommended clinical applications for both long-term and acute settings.

Conclusions:

  • Fondaparinux's in vivo acute efficacy may involve more than just FXa inhibition.
  • Factor IXa (FIXa) contributes to coagulation restart, suggesting a role for anti-FIXa activity.
  • Fondaparinux-AT's enhanced anti-FIXa activity might be critical for its acute clinical success.